DMYD B Share Price Performance
SEK 10.28
-2.90 (-22.00%)
Price SEK 10.28
Share PriceSEK 10.28
Diamyd Medical AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
DMYD B Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Diamyd Medical AB (publ) Key Details
Last Reported Earnings
Aug 31, 2025
Next Reporting Earnings
Nov 13, 2025
- -1.23
- -2,850.00%
- -130,597.69%
- 0%
About DMYD B
- Founded
- 1984
- Employees
- 33
- CEO
- WebsiteView website
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
